EUVIMEDEUVIMED entdecken
Crossref

Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in China

Genyong Zuo iD, Aijun Liu, Zunmin Zhu, Li Bao, Lihong Liu, Yongbo Gao, Wendong Chen iD, Rong Fu iD, Wenming Chen iD

Journal of Comparative Effectiveness Research · 2026-11 · 15 (11)

DOI: 10.57264/cer-2026-0146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-11. Verfasst von Genyong Zuo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Health Management & Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, C…. Hauptthemen laut MEDLINE: Multiple Myeloma, Boron Compounds, Glycine, Antibodies, Monoclonal. Die Arbeit nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Expanding treatment options for transplant-ineligible newly diagnosed multiple myeloma (ndMM) in China has increased the need to identify treatment strategies that improve patient outcomes while using healthcare resources efficiently. This study evaluated the cost-effectiveness of in-class transition (iCT) to ixazomib, lenalidomide and dexamethasone (IRd) versus daratumumab, lenalidomide and dexamethasone (DRd) for transplant-ineligible ndMM from the perspective of the Chinese healthcare system. Materials & methods: A cost-effectiveness analysis was conducted using a Markov cohort model that simulated lifetime health benefits and medical costs for the two treatment modalities. Model inputs were estimated from best available real-world evidence in the literature and from public data sources. Deterministic, probabilistic and scenario sensitivity analyses were performed to assess uncertainty in model results.

Results

In the base-case analysis, iCT IRd was projected to generate 0.580 additional quality-adjusted life years versus DRd (4.724 vs 4.144) and save lifetime medical costs by $7751. One-way sensitivity analysis indicated that cost-effectiveness was driven by uncertainty in model inputs related to treatment discontinuation and subsequent disease progression. Probabilistic sensitivity analysis estimated that iCT IRd had 79.2%, 88.0% and 91.3% probabilities of being cost-effective at willingness-to-pay thresholds of one, two and three-times China’s 2025 gross domestic product per capita per quality-adjusted life year, respectively.

Conclusion

Based on best available real-world evidence, the iCT IRd modality could be cost-effective compared with the DRd modality for transplant-ineligible patients with ndMM in China. Future real-world studies are needed to confirm the projected outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaBoron CompoundsGlycineAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsHumansCost-Benefit AnalysisCost-Effectiveness AnalysisChinaDexamethasoneMarkov ChainsQuality-Adjusted Life YearsLenalidomideBridge Therapy

Stichwörter der Autor:innen

Chinacost-effectiveness analysisdaratumumabixazomibmultiple myeloma

Substanzen

Boron CompoundsdaratumumabixazomibDexamethasoneGlycineAntibodies, MonoclonalLenalidomideAntineoplastic Agents

Autor:innen und Institutionen

  • Centre for Health Management & Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, China.
  • NHC Key Lab of Health Economics & Policy Research, Shandong University, Jinan, Shandong, 250012, China.
  • Department of Hematology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, 100020, China.
  • School of Clinical Medicine, Zhengzhou University, Zhengzhou, Henan, 450000, China.
  • Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, Henan, 450000, China.
  • Department of Hematology, Beijing Jishuitan Hospital, Beijing, 100096, China.

ORCID-Profile: Genyong Zuo, Wendong Chen, Rong Fu, Wenming Chen

Zitieren

APA

Zuo, G., Liu, A., Zhu, Z., Bao, L., Liu, L., Gao, Y., Chen, W., Fu, R., & Chen, W. (2026). Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in China. Journal of Comparative Effectiveness Research, 15(11). https://doi.org/10.57264/cer-2026-0146

Vancouver

Zuo G, Liu A, Zhu Z, Bao L, Liu L, Gao Y, et al. Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in China. Journal of Comparative Effectiveness Research. 2026;15(11). doi:10.57264/cer-2026-0146

BibTeX
@article{Zuo2026,
  author = {Zuo, Genyong and Liu, Aijun and Zhu, Zunmin and Bao, Li and Liu, Lihong and Gao, Yongbo and Chen, Wendong and Fu, Rong and Chen, Wenming},
  title = {Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in China},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.57264/cer-2026-0146}
}
Kostenlos starten →